Prevalence of dyslipidemia in Iran: A systematic review and meta-analysis study

International Journal of Preventive Medicine

Volumn 5, Issue 4, 2014, Pages 373-393

  Tabatabaei Malazy, Ozra ^a   Qorbani, Mostafa ^b,c   Samavat, Tahereh ^d   Sharifi, Farshad ^a   Larijani, Bagher ^a   Fakhrzadeh, Hossein ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ALBORZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

Author keywords

Cardiovascular disease; Dyslipidemia; Iran

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DISEASE CONTROL; DYSLIPIDEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INCIDENCE; IRAN; LIPID ANALYSIS; PREVALENCE; REVIEW; RISK REDUCTION; RURAL AREA; SEX DIFFERENCE; SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; URBAN AREA; URBANIZATION;

EID: 84899421403     PISSN: 20087802     EISSN: 20088213     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Alwan A. 2008-2013 Action Plan for the Global Strategy for the Prevention and Control of Noncommunicable Diseases. Report World Health Organization. Published 2009. Available in http://www.who.int/nmh/publications/9789241597418/en.
2. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997;349:1269-76.
3. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-504.
4. Critchley J, Liu J, Zhao D, Wei W, Capewell S. Explaining the increase in coronary heart disease mortality in Beijing between 1984 and 1999. Circulation 2004;110:1236-44.
5. Fakhrzadeh H, Pourebrahim R, Akhlaghi MR. Direct medical cost of coronary heart disease in Iran oil industry. Iran S Med J 2001;1:45-52.
6. Allender S, Scarborough P, Peto V, Leal J, Luengo-Fernandez R, Gray A. European Cardiovascular Disease Statistics. 2008 ed.: European Heart Network; 2008. Available in http://www.healtheurope.org/index
7. Williams KJ, Tabas I. Lipoprotein retention - And clues for atheroma regression. Arterioscler Thromb Vasc Biol 2005;25:1536-40.
8. Carroll MD, Lacher DA, Sorlie PD, Cleeman JI, Gordon DJ, Wolz M, et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA 2005;294:1773-81.
9. Wu Z, Yao C, Zhao D, Wu G, Wang W, Liu J, et al. Cardiovascular disease risk factor levels and their relations to CVD rates in China - Results of Sino-MONICA project. Eur J Cardiovasc Prev Rehabil 2004;11:275-83.
10. Bennet A, Di Angelantonio E, Erqou S, Eiriksdottir G, Sigurdsson G, Woodward M, et al. Lipoprotein (a) levels and risk of future coronary heart disease: Large-scale prospective data. Arch Intern Med 2008;168:598-608.
11. Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, et al. Lipoprotein (a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009;302:412-23.
12. Miller NE, Thelle DS, Forde OH, Mjos OD. The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: A prospective case-control study. Lancet 1977;1:965-8.
13. Bostom AG, Cupples LA, Jenner JL, Ordovas JM, Seman LJ, Wilson PW, et al. Elevated plasma lipoprotein (a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA 1996;276:544-8.
14. Keys A. Seven Countries: A Multivariate Analysis of Death and Coronary Heart Disease. Cambridge, MA: Harvard University Press; 1980.
15. Keil U, Kuulasmaa K. The WHO MONICA project: Risk factors. Int J Epidemiol 1989; 18 (3 Suppl 1):S46-55.
16. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356, 222 primary screenees of the multiple risk factor intervention trial (MRFIT). JAMA 1986;256:2823-8.
17. Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med 1979;90:85-91.
18. Robertson TL, Kato H, Rhoads GG, Kagan A, Marmot M, Syme SL, et al. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California. Incidence of myocardial infarction and death from coronary heart disease. Am J Cardiol 1977;39:239-43.
19. Carlson LA, Rosenhamer G. Reduction of mortality in the stockholm ischaemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988;223:405-18.
20. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994;308:367-72.
21. Harper CR, Jacobson TA. New perspectives on the management of low levels of high-density lipoprotein cholesterol. Arch Intern Med 1999;159:1049-57.
22. Rosenson RS. Low HDL-C: A secondary target of dyslipidemia therapy. Am J Med 2005;118:1067-77.
23. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15.
24. Abbott RD, Yano K, Hakim AA, Burchfiel CM, Sharp DS, Rodriguez BL, et al. Changes in total and high-density lipoprotein cholesterol over 10-and 20-year periods (the Honolulu Heart Program). Am J Cardiol 1998;82:172-8.
25. Abbott RD, Wilson PW, Kannel WB, Castelli WP. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study. Arteriosclerosis 1988;8:207-11.
26. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Mänttäri M, Heinonen OP, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992;85:37-45.
27. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-10.
28. Rafiei M, Boshtam M, Sarraf-Zadegan N. Lipid profiles in the Isfahan population: An Isfahan cardiovascular disease risk factor survey, 1994. East Mediterr Health J 1999;5:766-77.
29. Navaei L, Mehrabi Y, Azizi F. Epidemiology of hyperlipidemia, obesity and increased blood pressure in rural areas of Tehran Province. Iran J Endocrinol Metab 2000;2:253-62.
30. Barzygar A, Tehrani HS. Prevalence of atherosclerosis risk factors in the Some'esara city in 1996. J Kerman Univ Med Sci 1997;4:182-9.
31. st ed. 2002.
32. Fakhrzadeh H, Nabipour I, Rayani M, Vasiq A. Angina and myocardial infarction in patients with hyperlipidemia in Bushehr: A population-based study. Iran J Diabetes Lipid Disord 2002;2:65-73.
33. Saeedi MR, Ray A, Rezaei M. Prevalence of hyperlipidemia among adult residents of Kermanshah in 1997-1998. Scientific Journal of Kurdistan University of Medical Sciences 2003;3:49-54.
34. Karimi F, Rayani M, Akbarzadeh S, Khakzad M, Tahmasebi R, Arab J, et al. Prevalence of hyperlipidemias in adult population (>=19 years) of Bushehr Port; 1999. Iran S Med J 2000;3:98-106.
35. Azizi F, Rahmani M, Emami H, Mirmiran P, Hajipour R, Madjid M, et al. Cardiovascular risk factors in an Iranian urban population: Tehran lipid and glucose study (phase 1). Soz Praventivmed 2002;47:408-26.
36. Fakhrzadeh H, Larijani B, Bndarian F, Adibi H, Samavat T, Malek Afzali H, et al. Ischemic heart disease associated with coronary risk factors in the population over 25 years of Qazvin: Apopulation-based study. The Journal of Qazvin University of Medical Sciences and Health Services 2005;35:26-34.
37. Shamseddini S, Zohor A, Vaji MB, Mirzaei F, Forod A, Kashani M. Blood lipid concentrations and its association with body mass index in the Kerman citizens. Armaghane Danesh 2002;7:8-15.
38. Mohamadi-fard N, Sadri GH, Sarraf-zadegan N, Baghaie AM, Shahrokhi SH, Hoseini SH, et al. The prevalence of cardiovascular risk factors in rural and urban population of Isfahan and Markazi provinces. The Journal of Qazvin University of Medical Sciences and Health Services 2003;7:5-14.
39. Fakhrzadeh H, Pourebrahim R, Nouri M, Nouri M, Shoushtarizadeh P, Pajouhi M. Distribution of risk factors for cardiovascular disease in the population covered Tehran's population laboratory. Iran J Diabetes Lipid Disord 2004;3 Suppl 1 (MONICA project):53-61.
40. Agheli N, AsifZadeh S, Rajabi M. Prevalence of risk factors for coronary heart disease in adults over 30 years of Rasht and Qazvin. The Journal of Qazvin University of Medical Sciences and Health Services 2005;35:59-65.
41. Amiri M, Emami SR, Nabipour I, Nosraty A, Iranpour D, Soltanian A, et al. Risk factors of cardiovascular diseases in Bushehr port on the basis of the WHO Monica project: The Persian Gulf Healthy Heart Project. Iran S Med J 2004;2:151-61.
42. EsmaeiliNadimi A, Kohanali JA. Lipid disorders in Rafsanjan urban population/phase I study of risk factors for coronary artery disease in Rafsanjan. Iran J Diabetes Lipid Disord 2004;3:149-54.
43. Namayandeh SM, Sadr SM, Ansarin Z, Rafiei M. A cross-sectional study of the prevalence of coronary artery disease traditional risk factors in Yazd urban population, Yazd healthy heart project. Iran Cardiovasc Res J 2011;5:7-13.
44. Nabipour I, Amiri M, Imami SR, Jahfari SM, Nosrati A, Iranpour D, et al. Unhealthy lifestyles and ischaemic electrocardiographic abnormalities: The Persian Gulf Healthy Heart Study. East Mediterr Health J 2008;14:858-68.
45. Seyffarshad M, Kousha A, Pourdowlati S, Karamouz M, Farahbakhsh M, Hakimi S, et al. Cardiac risk factor analysis in East Azerbaijan, Iran. Cardiology 2007;3:1-4.
46. Chehrei A, Sadrnia S, Keshteli AH, Daneshmand MA, Rezaei J. Correlation of dyslipidemia with waist to height ratio, waist circumference, and body mass index in Iranian adults. Asia Pac J Clin Nutr 2007;16:248-53.
47. Alikhani S, Delavari A, Alaedini F, Kelishadi R, Rohbani S, Safaei A. A province-based surveillance system for the risk factors of non-communicable diseases: A prototype for integration of risk factor surveillance into primary healthcare systems of developing countries. Public Health 2009;123:358-64.
48. Ghoddosi K, Ameli J, Saadat AR, Farziani VP, Poor FN, Karami GH, et al. Dyslipidemia and its relation with smoking in Tehran. Journal of Gorgan University of Medical Sciences 2006;8:55-9.
49. Javadi HR, Azimian J, Rajabi M, Kalantari Z, Javadi M, Esmaiilzadeh H, et al. Prevalence of cardiovascular risk factors among women in Minoodar district of Qazvin; Interventional propositions. The Journal of Qazvin University of Medical Sciences and Health Services 2009;13:35-43.
50. Hatmi ZN, Tahvildari S, Gafarzadeh Motlag A, Sabouri Kashani A. Prevalence of coronary artery disease risk factors in Iran: A population based survey. BMC Cardiovasc Disord 2007;7:32.
51. Asgari F, Mirzazadeh A, Miri AH. Iran Non-Communicable Diseases Risk Factors Surveillance, Data Book for 2007. Iran, Tehran: Ministry of Health and Medical Education. Deputy for Health Center for Non-Communicable Disease Control and Management; 2007. p. 1-82. Available in: www.who.int/chp/steps/2007STEPSreportIran.pdf.
52. Sharifi F, Mousavinasab SN, Soruri R, Saeini M, Dinmohammadi M. High prevalence of low high-density lipoprotein cholesterol concentrations and other dyslipidemic phenotypes in an Iranian population. Metab Syndr Relat Disord 2008;6:187-95.
53. Ministry of Health and Medical Education of Iran. NCD Survey 2011.
54. Azizi F, Etemadi A, Salehi P, Zahedi S. Prevalence of metabolic syndrome in an urban population: Tehran lipid and glucose study. Tehran Univ M J 2003;6:389-99.
55. Gharipour M, Bagheri A, Boshtam M, Rabiei K. Prevalence of metabolic syndrome among the adults of central of areas of Iran (as part of "Isfahan Healthy Heart Study"). Journal of Birjand University of Medical Sciences 2006;13:56-63.
56. Malek M, Ghorbani R, Rashidipour A, Eskandarian R. Prevalence of low HDL-C cholesterol-high triglycerides in the province of semnan (2005). Iran J Diabetes Lipid 2009;9:75-80.
57. Barzin M, Mirmiran P, Afghan M, Azizi F. Distribution of 10-year risk for coronary heart disease and eligibility for therapeutic approaches among Tehranian adults. Public Health 2011;125:338-44.
58. Azizi F, Ghanbarian A, Momenan AA, Hadaegh F, Mirmiran P, Hedayati M, et al. Prevention of non-communicable disease in a population in nutrition transition: Tehran lipid and glucose study phase II. Trials 2009;10:5.
59. st ed. Croatia: InTech; 2012. p. 303-20.
60. He J, Gu D, Reynolds K, Wu X, Muntner P, Zhao J, et al. Serum total and lipoprotein cholesterol levels and awareness, treatment, and control of hypercholesterolemia in China. Circulation 2004;110:405-11.
61. Sharma SK, Ghimire A, Radhakrishnan J, Thapa L, Shrestha NR, Paudel N, et al. Prevalence of hypertension, obesity, diabetes, and metabolic syndrome in Nepal. Int J Hypertens 2011;2011:821971.
62. Prasad DS, Kabir Z, Dash AK, Das BC. Coronary risk factors in South Asians: A prevalence study in an urban populace of Eastern India. CVD Prev Control 2010;5:125-32.
63. United Kingdom Food Standard Agency: The National Diet and Nutrition Survey: Adults aged 19-64 years (Summary Report). Available from: http://www.food.gov.uk/multimedia/pdfs/ndns5full.pdf. [Last accessed on 2004].
64. Costa J, Borges M, Oliveira E, Gouveia M, Carneiro AV. Incidence and prevalence of hypercholesterolemia in Portugal: A systematic review. Part III. Rev Port Cardiol 2003;22:829-36.
65. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics - 2013 update: A report from the American Heart Association. Circulation 2013;127:e6-245.
66. Al-Nozha MM, Arafah MR, Al-Maatouq MA, Khalil MZ, Khan NB, Al-Marzouki K, et al. Hyperlipidemia in Saudi Arabia. Saudi Med J 2008;29:282-7.
67. Erem C, Hacihasanoglu A, Deger O, Kocak M, Topbas M. Prevalence of dyslipidemia and associated risk factors among Turkish adults: Trabzon lipid study. Endocrine 2008;34:36-51.
68. Sibai AM, Obeid OA, Batal M, Adra N, El Khoury D, Hwalla N.Prevalence and correlates of metabolic syndrome in an adult Lebanese population. Prev Control 2008;3:83-90.
69. Hollman G, Kristenson M. The prevalence of the metabolic syndrome and its risk factors in a middle-aged Swedish population - Mainly a function of overweight? Eur J Cardiovasc Nurs 2008;7:21-6.
70. Miccoli R, Bianchi C, Odoguardi L, Penno G, Caricato F, Giovannitti MG, et al. Prevalence of the metabolic syndrome among Italian adults according to ATP III definition. Nutr Metab Cardiovasc Dis 2005;15:250-4.
71. Firmann M, Mayor V, Vidal PM, Bochud M, Pécoud A, Hayoz D, et al. The CoLaus study: A population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. BMC Cardiovasc Disord 2008;8:6.
72. Lin CC, Liu CS, Lai MM, Li CI, Chen CC, Chang PC, et al. Metabolic syndrome in a Taiwanese metropolitan adult population. BMC Public Health 2007;7:239.
73. Rampal S, Mahadeva S, Guallar E, Bulgiba A, Mohamed R, Rahmat R, et al. Ethnic differences in the prevalence of metabolic syndrome: Results from a multi-ethnic population-based survey in Malaysia. PLoS One 2012;7:e46365.
74. Mula-Abed WA, Chilmeran SK. Prevalence of dyslipidemia in the Iraqi adult population. Saudi Med J 2007;28:1868-74.
75. Al-Lawati JA, Mohammed AJ, Al-Hinai HQ, Jousilahti P. Prevalence of the metabolic syndrome among Omani adults. Diabetes Care 2003;26:1781-5.
76. Bahreynian M, Esmaillzadeh A. Quantity and quality of carbohydrate intake in Iran: A target for nutritional intervention. Arch Iran Med 2012;15:648-9.
77. Lee MH, Kim HC, Ahn SV, Hur NW, Choi DP, Park CG, et al. Prevalence of dyslipidemia among Korean adults: Korea National Health and Nutrition Survey 1998-2005. Diabetes Metab J 2012;36:43-55.
78. Ghayour-Mobarhan M, Kazemi-Bajestani SM, Ferns G. Lipid clinics are urgently required in the Iranian public health system. Int J Prev Med 2010;1:172-5.